Jingjia reports 2022 H1 revenue increase

Aug.22.2022
Jingjia reports 2022 H1 revenue increase
Jinjia achieved revenue growth despite challenges in the tobacco business, with promising growth in the new tobacco industry.

Jingtian & Gongcheng, a company listed on the Shenzhen Stock Exchange under the symbol 002191.SZ, has released its H1 2022 financial report. The report shows that the company has achieved operating revenue of CNY 2.644 billion, an increase of 8.03% year-on-year. The net profit attributable to shareholders of the listed company amounted to CNY 500 million, a decrease of 1.40% year-on-year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses amounted to CNY 425 million, a decrease of 11.29% year-on-year. The basic earnings per share is CNY 0.34/share.


During the reporting period, the revenue from cigarette label products decreased by 9.56% compared to the same period last year. The company's cigarette label business experienced some fluctuations due to factors such as intensified regional market competition, decreased bidding prices, fluctuating production raw material costs, and sporadic COVID-19 outbreaks.


During the reporting period, the company achieved a 297.53% increase in revenue from its new tobacco business compared to the same period last year. The company has been actively adapting to new regulations surrounding electronic cigarettes, streamlining and optimizing the mechanism and processes of cooperation among the entities in its new tobacco industry chain. This strategy has effectively leveraged the company's resources, resulting in overall positive growth in areas such as technology research and development, new product development, and customer collaboration. As such, the company has been able to successfully implement high-quality strategies for advancing its new tobacco development plans.


This article contains excerpts or reprints of third-party information. The copyright belongs to the original media and author. If there is any infringement, please contact us for deletion. Any organization or individual who wishes to reproduce this content should contact the author directly and refrain from direct reproduction.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

UK Launches Call for Evidence to Shape New Tobacco and Vapes Regulations
UK Launches Call for Evidence to Shape New Tobacco and Vapes Regulations
The UK's Department of Health and Social Care (DHSC) has launched an eight-week comprehensive call for evidence to inform new regulations under the forthcoming Tobacco and Vapes Bill, with a deadline of December 3, 2025. The initiative aims to systematically gather evidence on vape flavors, ingredients, nicotine levels, and product design, as well as proposals for an omnichannel retail licensing scheme for tobacco and vapes and a new product registration system.
Nov.04 by 2FIRSTS.ai
Luxembourg Passes Bill 8333: Heated Tobacco and Nicotine Pouches Regulated
Luxembourg Passes Bill 8333: Heated Tobacco and Nicotine Pouches Regulated
Luxembourg’s Chamber of Deputies adopted Bill No. 8333, transposing EU Directive 2022/2100 and extending tobacco controls to heated tobacco, e-cigarettes and nicotine pouches. The law bans flavourings, restricts sales to minors, and caps nicotine content at 0.048 mg per pouch. CBD and caffeine additives are prohibited.
Nov.03 by 2FIRSTS.ai
Heno Biotech Releases 2024 ESG Report at Inter Tabac, Setting a New Global Benchmark for the Nicotine Industry Through Green Development and Compliance Governance
Heno Biotech Releases 2024 ESG Report at Inter Tabac, Setting a New Global Benchmark for the Nicotine Industry Through Green Development and Compliance Governance
At InterTabac, the world’s largest tobacco industry exhibition in Dortmund, Germany, Heno Biotech released its 2024 Environmental, Social, and Governance (ESG) Report. As a leading enterprise in China’s natural nicotine sector, Heno presented its third consecutive annual ESG disclosure, highlighting achievements in green development, compliance governance, and social responsibility, setting a new benchmark for sustainable growth in the industry.
Sep.18
Spanish Police Seize Over 24,000 Smuggled E-Cigarettes; Two Arrested on Multiple Charges
Spanish Police Seize Over 24,000 Smuggled E-Cigarettes; Two Arrested on Multiple Charges
The Spanish Civil Guard carried out an operation targeting e-cigarette smuggling and illegal distribution, seizing a total of 24,520 e-cigarettes of unknown origin valued at approximately €312,000.
Oct.10 by 2FIRSTS.ai
Product | Three Power Levels + “2+10” Setup: ELFBAR JoinOne Series Launches in UK Retail
Product | Three Power Levels + “2+10” Setup: ELFBAR JoinOne Series Launches in UK Retail
ELFBAR rolls out the JoinOne15 Classic prefilled replaceable-pod kit, now listed across multiple UK e-commerce channels (some pages marked “coming soon”). The device uses a “2 ml prefilled pod + 10 ml refill container (‘2+10’)” system, supports three power levels, and claims up to 15,000 puffs in combined use. The kit is priced at £12.99, with matching “2+10” refill pods at £7.99.
Nov.03 by 2FIRSTS.ai
FDA’s Makary on CNN: The Triple Challenge in Vape Regulation — New Opioids, Illicit Trade, and Youth Protection
FDA’s Makary on CNN: The Triple Challenge in Vape Regulation — New Opioids, Illicit Trade, and Youth Protection
In an interview with CNN’s Chasing Life, U.S. Food and Drug Administration (FDA) Commissioner Dr. Marty Makary warned that new health risks — from emerging opioids such as 7-OH to unregulated vaping products — are slipping through regulatory cracks. His remarks reveal the FDA’s growing challenge to balance harm reduction for adult smokers with youth protection and cross-border enforcement.
Oct.10